Retatrutide Significantly Improves Body Composition in People with Type 2 Diabetes

Type 2 diabetes is a chronic metabolic condition often associated with obesity and an unfavorable body composition, characterized by excess fat mass and reduced lean mass, which exacerbates health risks. While current treatments primarily focus on glycemic control, there is a critical need for therapies that also effectively improve body composition, particularly by reducing fat mass while preserving crucial lean muscle mass. This study investigated how retatrutide, a novel triple agonist, impacts body composition in individuals with type 2 diabetes.

Patients receiving retatrutide demonstrated dose-dependent and statistically significant improvements in body composition compared to placebo. The highest dose group (12 mg) showed a mean total body weight reduction of 15.7% (p<0.001) from baseline over 24 weeks, significantly greater than the 2.5% reduction observed in the placebo group. The most impactful finding was a 35% (p<0.001) reduction in total fat mass in the 12 mg retatrutide group, with approximately 80% of the total weight loss attributed to fat mass, significantly preserving lean muscle mass. Visceral fat mass, a key indicator of metabolic risk, was also robustly reduced by 40% (p<0.001) in the high-dose group, indicating a highly favorable shift in fat distribution. Lean mass was largely preserved, showing only a 5% reduction, which is significantly less than typically observed with similar magnitudes of weight loss achieved through diet alone.